For the Inventor, By the Inventor

Enter assignee name

Cellectis

USPTO Granted Patents = 101

% Expired Patents = 12.9

CIPO Patents = 5

EPO Patents = 90

Trademarks = 3

Forward Citations = 419

Loading Chart...

Loading Chart...

79 inventors (with patents filed for the assignee):

Philippe Duchateau (45 out of 55 patents)

Laurent Poirot (38 out of 39 patents)

Roman Galetto (22 out of 27 patents)

4. Julianne Smith (21 out of 23 patents)

5. Andrew M Scharenberg (18 out of 47 patents)

6. Julien Valton (16 out of 19 patents)

7. Agnes Gouble (14 out of 14 patents)

8. Alexandre Juillerat (12 out of 19 patents)

9. Stephanie Grosse (11 out of 11 patents)

10. Cecile Mannioui (9 out of 9 patents)

11. Jean-Pierre Cabaniols (8 out of 8 patents)

12. Cécile Schiffer-Mannioui (7 out of 7 patents)

13. David Sourdive (7 out of 7 patents)

14. Jean-Charles Epinat (7 out of 12 patents)

15. André Choulika (6 out of 11 patents)

Core Competencies:

Chimeric Antigen Receptors

Gene Editing

T Cell Engineering

Immunotherapy

Cancer Treatment

CRISPR Technology

T Cell Resistance

Targeted Gene Insertion

Allogeneic T Cells

Immune Cell Therapy

Tumor Microenvironment

101 patents: Sort by Forward Citations

1. 12753220 - New mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy (2026-10-06),

2. 12680076 - METHODS FOR ENGINEERING ALLOGENEIC AND HIGHLY ACTIVE T CELL FOR IMMUNOTHERAPHY (2026-07-14),

3. 12655451 - TAL- effector nuclease (TALEN) -MODIFIED ALLOGENIC CELLS SUITABLE FOR THERAPY (2026-06-16),

4. 12577581 - USE OF PRE T ALPHA OR FUNCTIONAL VARIANT THEREOF FOR EXPANDING TCR ALPHA DEFICIENT T CELLS (2026-03-17),

5. 12391933 - Targeted gene insertion for improved immune cells therapy (2025-08-19),

6. 12365733 - Method for improving production of car T cells (2025-07-22),

7. 12252699 - Method for generating t-cells compatible for allogenic transplantation (2025-03-18),

8. 12221478 - Targeted gene integration of CRS inhibitor genes for improved immune cells therapy (2025-02-11),

9. 12209125 - Targeted gene integration of NK inhibitors genes for improved immune cells therapy (2025-01-28),

10. 12171820 - Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment (2024-12-24),

11. 12144825 - Cellular immunotherapy for repetitive administration (2024-11-19),

12. 12012607 - Engineering wheat with increased dietary fiber (2024-06-18),

13. 11987639 - Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for cancer immunotherapy (2024-05-21),

14. 11959091 - Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system (2024-04-16),

15. 11919961 - CD123 specific chimeric antigen receptors for cancer immunotherapy (2024-03-05),

Company Overview

Cellectis is a pioneering biotechnology company based in Paris, France, specializing in cancer immunotherapy. The organization focuses on developing innovative treatments that harness the power of the immune system to target and eliminate cancer cells. Key areas of expertise include chimeric antigen receptors (CARs), gene editing, and T cell engineering, utilizing advanced technologies such as CRISPR for precise gene modifications. Cellectis aims to transform cancer treatment through its commitment to research and development in immunotherapy and targeted gene insertion.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

101 Patents

#80 in Paris

#270 in France

#7,721 in the World

Cellectis

Forward Citations = 419

79 inventors:

Philippe Duchateau (45 out of 55 patents)

Laurent Poirot (38 out of 39 patents)

Roman Galetto (22 out of 27 patents)

4. Julianne Smith (21 out of 23 patents)

5. Andrew M Scharenberg (18 out of 47 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cellectis. Retrieved from https://idiyas.com/company/cellectis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…